Revolution Medicines Rises on Daraxonrasib Data Revolution shares jumped ~46% on Apr 13, 2026 after daraxonrasib showed a 44% ORR in an 18-patient pancreatic cohort (Revolution press release Apr 12, 2026).

Revolution Medicines Rises on Daraxonrasib Data: Revolution shares jumped ~46% on Apr 13, 2026 after daraxonrasib showed a 44% ORR in an 18-patient pancreatic cohort (Revolution press release Apr 12,… 👈 Read full analysis #RevolutionMedicines #Daraxonrasib #PancreaticCancer #CancerResearch #Biotech

Revolution rockets on strong pancreatic cancer data Revolution Medicines thinks it could transform the treatment of pancreatic cancer based on phase 3 data with its pan-RAS(on) inhibitor daraxonrasib

#RevolutionMedicines thinks it could transform the treatment of #pancreaticcancer – one of the hardest forms to treat – based on phase 3 data with its pan-RAS(on) inhibitor #daraxonrasib.

pharmaphorum.com/news/revolut...

Revolution Medicines Rises on Daraxonrasib Data Revolution shares jumped ~46% on Apr 13, 2026 after daraxonrasib showed a 44% ORR in an 18-patient pancreatic cohort (Revolution press release Apr 12, 2026).

Revolution Medicines Rises on Daraxonrasib Data: Revolution shares jumped ~46% on Apr 13, 2026 after daraxonrasib showed a 44% ORR in an 18-patient pancreatic cohort (Revolution press release… 👈 Read full analysis #RevolutionMedicines #Daraxonrasib #PancreaticCancer #CancerResearch #Pharmaceuticals

Revolution Medicines' Daraxonrasib Wins Phase 3 Trial Revolution Medicines reported Phase 3 success for daraxonrasib on Apr 13, 2026, affecting ~64,000 U.S. pancreatic cancer cases/year and a disease with ~12% 5-year survival.

Revolution Medicines' Daraxonrasib Wins Phase 3 Trial: Revolution Medicines reported Phase 3 success for daraxonrasib on Apr 13, 2026, affecting ~64,000 U.S. pancreatic cancer cases/year and a… 👈 Read full analysis #RevolutionMedicines #Daraxonrasib #Phase3Trial #PancreaticCancer #CancerResearch

Daraxonrasib Draws Attention After Ben Sasse Disclosure Ben Sasse's Apr 10, 2026 disclosure spotlights daraxonrasib; pancreatic cancer has a ~12% 5-year survival, intensifying focus on early clinical readouts.

Daraxonrasib Draws Attention After Ben Sasse Disclosure: Ben Sasse's Apr 10, 2026 disclosure spotlights daraxonrasib; pancreatic cancer has a ~12% 5-year survival, intensifying focus on early clinical… 👈 Read full analysis #Daraxonrasib #PancreaticCancer #BenSasse #CancerResearch #ClinicalTrials

Daraxonrasib Earns FDA Breakthrough Status in Pancreatic Cancer Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Le #FDA a accordé la désignation de "thérapie révolutionnaire" au #Daraxonrasib 💊 pour le traitement des patients atteints du #CancerDuPancréas métastatiques précédemment traités porteurs de mutations #KRAS #G12X
www.targetedonc.com/view/daraxon...